Our Mission

At Skye Bioscience, our focus is to contribute new mechanisms and drugs with the potential to help build the mosaic of therapeutic approaches and benefits that are necessary to serve the growing population of patients with diverse needs related to obesity and comorbid metabolic conditions.

Our Values

Collaboration

We support a collaborative environment and know it takes people with different ideas, strengths, interests, and cultural backgrounds to make our company succeed.

Passion

Passion is at the heart of our company and drives every initiative. It is through our passion that we have fostered a unique relationship between business, medicine, and people; one that is personal and authentic.

Integrity

We uphold the highest standards of integrity in all that we do.

Accountability

We are accountable to each other and the patients we serve.

Quality

We take pride in advancing high-quality science that could translate into potentially transformative therapies for diseases with unmet needs.

Management
President & CEO Punit Dhillon

Mr. Dhillon has been the President and Chief Executive Officer of Skye Bioscience since 2020. He has a 20-year track record as an executive and investor in the life sciences industry.

Skye Bioscience Photograph

Mr. Dhillon has been the President and Chief Executive Officer of Skye Bioscience since 2020. He has a 20-year track record as an executive and investor in the life sciences industry.

Focusing on early-stage biotechs from start-up through clinical proof-of-concept, he has raised more than $500 million in capital and established multiple pharmaceutical partnerships. At Skye he led the strategic acquisition of a novel peripheral CB1 inhibitor for obesity and other metabolic diseases, attracted specialist life science investors, and built out an expert board and management team. Mr. Dhillon was previously the co-founder and former CEO of OncoSec Medical, a developer of cancer immunotherapies and established collaborations with Merck and Genentech.

Prior to Skye he was a managing director of a private San Diego-based pharmaceutical company where he launched an Asia-focused licensing business unit evaluating opportunities in Korea, China, Japan, and the US, and completed a partnership with BMS. He was formerly a director of the Emerald group of companies with responsibility for private equity investments, operations and business development. As Vice President, Finance and Operations, at Inovio Pharmaceuticals he completed licensing deals with Merck, Wyeth (now Pfizer) and Roche. Punit holds a BA (Honors) in political science and a minor in business administration from Simon Fraser University.

Chief Financial Officer Kaitlyn Arsenault, CPA
Skye Bioscience Photograph

Ms. Arsenault brings over 16 years of experience in accounting, auditing, financial reporting, mergers and acquisitions, as well as business operations in the life science and technology sectors.

Prior to her appointment as CFO of Skye, she served as an independent consultant for emerging public and private companies, including Skye, for over six years, providing expertise and addressing complex issues related to SEC reporting, technical accounting, stock-based compensation, and revenue recognition, among other subjects. She also served as Assurance Manager in Marcum’s (formerly Friedman LLP’s) SEC practice, gaining public and private audit engagement experience across multiple industries. Ms. Arsenault received her Bachelor of Science degree in accounting from Ramapo College of New Jersey and is a Certified Public Accountant.

Chief Development Officer Tu Diep, MSc
Skye Bioscience Photograph

Mr. Tu Diep brings more than 15 years of scientific and clinical research experience to Skye. He was a founding employee of OncoSec Medical Inc. and in his last role was SVP, Head of Operations.

He led the development and initiation of OncoSec’s lead program, tavokinogene telsaplasmid (TAVO), an intratumoral gene therapy using DNA plasmid encoding interleukin-12, and spearheaded a clinical collaboration with Merck to evaluate the combination of TAVO plus pembrolizumab, Merck’s anti-PD-1 antibody for metastatic melanoma. Mr. Diep was previously at Protox Therapeutics Inc. (now Sophiris Bio Inc.), holding roles in preclinical research and development, clinical protocol development and design, clinical operations, and biologics manufacturing related to their cancer treatment. He was also integrally involved in solidifying a $75M partnership with a Japanese pharmaceutical company and a $35M investment from Warburg Pincus. Mr. Diep holds a Master of Science in physiology from the University of Toronto.

Chief Scientific Officer Chris Twitty, PhD
Skye Bioscience Photograph

Dr. Twitty brings over 25 years of life science research and drug development experience to Skye.

Dr. Twitty led R&D and translational efforts to expand drug pipelines and has supported multiple IND filings for novel therapeutics. He has additionally contributed to CMC, non-clinical, regulatory and clinical development efforts necessary to initiate clinical trials. He has significant experience in biomarker discovery and clinical biomarker strategies. Dr. Twitty was previously Chief Scientific Officer at Onchilles Pharma. Prior to that he was Director and Head of Clinical Sciences and then VP of R&D and CSO at Oncosec Medical. He began his career at Bayer and worked in research at Cell Genesys and Tocagen. He is a co-author of 19 publications and a named inventor on three patents. Dr. Twitty holds a PhD Molecular Microbiology and Immunology from Oregon Health Sciences University. He was a post-doctoral fellow with the Earle A. Chiles Research Institute.

Chief Medical Officer Puneet S. Arora, MD, MS, FACE
Skye Bioscience Photograph

Puneet S. Arora is a board-certified physician in endocrinology, diabetes and metabolism, and has served as a physician-scientist, drug developer and executive leader.

Dr. Arora has over 15 years of experience in clinical trials, regulatory submissions, and medical affairs in biotech and pharma. As Chief Medical Officer at Lassen Therapeutics, he was instrumental in developing a strategy leading to a global Phase 2 study. Previously, as Head of Clinical Development at Principia Biopharma, a Sanofi company, he managed the clinical development strategy and oversaw design and execution of clinical studies. At Genentech, he was Senior Medical Director, Early Clinical Development, and lead programs in diabetes, obesity, and NASH. Dr. Arora has authored or co-authored numerous peer-reviewed publications in prestigious journals and presented at international scientific conferences. He earned his medical degree from the All India Institute of Medical Science, completed his internal medicine residency at Southern Illinois University, and held a fellowship in endocrinology at NYU. He earned a Master’s in Clinical Research from the Mayo Clinic and held an advanced diabetes fellowship at the Mayo Graduate School of Medicine.

General Counsel Brennen Brodersen, JD
Skye Bioscience Photograph

Mr. Brodersen brings over a decade of experience representing biopharmaceutical and life science focused companies on a wide variety of corporate legal matters.

Prior to joining Skye, Mr. Brodersen was a senior associate at Morrison & Foerster, LLP, advising biopharmaceutical companies in all stages of development, from formation to early stage financing, on IPOs, M&A transactions, and public company representation. Brennen received his J.D. from the University of California Los Angeles (UCLA) School of Law and a B.A. in economics from UCLA.

President & CEO Punit Dhillon

Mr. Dhillon has been the President and Chief Executive Officer of Skye Bioscience since 2020. He has a 20-year track record as an executive and investor in the life sciences industry.

Skye Bioscience Photograph

Mr. Dhillon has been the President and Chief Executive Officer of Skye Bioscience since 2020. He has a 20-year track record as an executive and investor in the life sciences industry.

Focusing on early-stage biotechs from start-up through clinical proof-of-concept, he has raised more than $500 million in capital and established multiple pharmaceutical partnerships. At Skye he led the strategic acquisition of a novel peripheral CB1 inhibitor for obesity and other metabolic diseases, attracted specialist life science investors, and built out an expert board and management team. Mr. Dhillon was previously the co-founder and former CEO of OncoSec Medical, a developer of cancer immunotherapies and established collaborations with Merck and Genentech.

Prior to Skye he was a managing director of a private San Diego-based pharmaceutical company where he launched an Asia-focused licensing business unit evaluating opportunities in Korea, China, Japan, and the US, and completed a partnership with BMS. He was formerly a director of the Emerald group of companies with responsibility for private equity investments, operations and business development. As Vice President, Finance and Operations, at Inovio Pharmaceuticals he completed licensing deals with Merck, Wyeth (now Pfizer) and Roche. Punit holds a BA (Honors) in political science and a minor in business administration from Simon Fraser University.

Chief Financial Officer Kaitlyn Arsenault, CPA
Skye Bioscience Photograph

Ms. Arsenault brings over 16 years of experience in accounting, auditing, financial reporting, mergers and acquisitions, as well as business operations in the life science and technology sectors.

Prior to her appointment as CFO of Skye, she served as an independent consultant for emerging public and private companies, including Skye, for over six years, providing expertise and addressing complex issues related to SEC reporting, technical accounting, stock-based compensation, and revenue recognition, among other subjects. She also served as Assurance Manager in Marcum’s (formerly Friedman LLP’s) SEC practice, gaining public and private audit engagement experience across multiple industries. Ms. Arsenault received her Bachelor of Science degree in accounting from Ramapo College of New Jersey and is a Certified Public Accountant.

Chief Development Officer Tu Diep, MSc
Skye Bioscience Photograph

Mr. Tu Diep brings more than 15 years of scientific and clinical research experience to Skye. He was a founding employee of OncoSec Medical Inc. and in his last role was SVP, Head of Operations.

He led the development and initiation of OncoSec’s lead program, tavokinogene telsaplasmid (TAVO), an intratumoral gene therapy using DNA plasmid encoding interleukin-12, and spearheaded a clinical collaboration with Merck to evaluate the combination of TAVO plus pembrolizumab, Merck’s anti-PD-1 antibody for metastatic melanoma. Mr. Diep was previously at Protox Therapeutics Inc. (now Sophiris Bio Inc.), holding roles in preclinical research and development, clinical protocol development and design, clinical operations, and biologics manufacturing related to their cancer treatment. He was also integrally involved in solidifying a $75M partnership with a Japanese pharmaceutical company and a $35M investment from Warburg Pincus. Mr. Diep holds a Master of Science in physiology from the University of Toronto.

Chief Scientific Officer Chris Twitty, PhD
Skye Bioscience Photograph

Dr. Twitty brings over 25 years of life science research and drug development experience to Skye.

Dr. Twitty led R&D and translational efforts to expand drug pipelines and has supported multiple IND filings for novel therapeutics. He has additionally contributed to CMC, non-clinical, regulatory and clinical development efforts necessary to initiate clinical trials. He has significant experience in biomarker discovery and clinical biomarker strategies. Dr. Twitty was previously Chief Scientific Officer at Onchilles Pharma. Prior to that he was Director and Head of Clinical Sciences and then VP of R&D and CSO at Oncosec Medical. He began his career at Bayer and worked in research at Cell Genesys and Tocagen. He is a co-author of 19 publications and a named inventor on three patents. Dr. Twitty holds a PhD Molecular Microbiology and Immunology from Oregon Health Sciences University. He was a post-doctoral fellow with the Earle A. Chiles Research Institute.

Chief Medical Officer Puneet S. Arora, MD, MS, FACE
Skye Bioscience Photograph

Puneet S. Arora is a board-certified physician in endocrinology, diabetes and metabolism, and has served as a physician-scientist, drug developer and executive leader.

Dr. Arora has over 15 years of experience in clinical trials, regulatory submissions, and medical affairs in biotech and pharma. As Chief Medical Officer at Lassen Therapeutics, he was instrumental in developing a strategy leading to a global Phase 2 study. Previously, as Head of Clinical Development at Principia Biopharma, a Sanofi company, he managed the clinical development strategy and oversaw design and execution of clinical studies. At Genentech, he was Senior Medical Director, Early Clinical Development, and lead programs in diabetes, obesity, and NASH. Dr. Arora has authored or co-authored numerous peer-reviewed publications in prestigious journals and presented at international scientific conferences. He earned his medical degree from the All India Institute of Medical Science, completed his internal medicine residency at Southern Illinois University, and held a fellowship in endocrinology at NYU. He earned a Master’s in Clinical Research from the Mayo Clinic and held an advanced diabetes fellowship at the Mayo Graduate School of Medicine.

General Counsel Brennen Brodersen, JD
Skye Bioscience Photograph

Mr. Brodersen brings over a decade of experience representing biopharmaceutical and life science focused companies on a wide variety of corporate legal matters.

Prior to joining Skye, Mr. Brodersen was a senior associate at Morrison & Foerster, LLP, advising biopharmaceutical companies in all stages of development, from formation to early stage financing, on IPOs, M&A transactions, and public company representation. Brennen received his J.D. from the University of California Los Angeles (UCLA) School of Law and a B.A. in economics from UCLA.

Chairman of the Board Paul Grayson

Paul Grayson brings over 25 years’ experience in the biotech sector.

Mr. Grayson serves as Chief Executive Officer of Radionetics. He has been focusing on company origination, platform validation, IND enablement, and large and small molecule CMC through clinical proof of concept across a broad range of technologies and applications as both a CEO and a Venture Partner over the past 25 years. He was most recently the President and CEO of Tentarix Biotherapeutics, an oncology company focused on multi-functional biologics. His previous experiences also include founding roles at BirdRock Bio (acquired by Skye Biosciences), Fate Therapeutics (NASDAQ: FATE), Senomyx (acquired by Firmenich), and Aurora Biosciences (acquired by Vertex Pharmaceuticals).

Director Deborah Charych, PhD

Deborah Charych, PhD has over 20 years of experience in the biotech and pharmaceutical industry.

Dr. Deborah Charych brings extensive experience in scientific leadership to her role as a co-founder and former Chief Technology Officer of RayzeBio, an oncology company focused on targeted delivery of radionuclides. She conceived and led the scientific and operational R&D strategy for RayzeBio, which led to a successful $45M Series A financing and launch in August, 2020, and subsequent Series B, C and D rounds, with capital raised amounting to $418M. Previously, at Nektar Therapeutics Dr. Charych conceived and led the preclinical and early clinical development of an immuno-oncology pipeline, leading to a $1.8B upfront deal with Bristol Myers Squibb. She also contributed to basic research exploring GPCR receptor biology including the cannabinoid receptor system. At FivePrime Therapeutics, Deborah led a team developing biologics for oncology and autoimmune diseases. While at Chiron Corporation she initiated and led a large proteomics effort to guide oncology target discovery. At Lawrence Berkeley National Laboratory, she led an academic team as a tenured principal investigator, focusing on new biomaterials. Dr. Charych has a Ph.D. in Chemistry from UC Berkeley and a B.S. in Chemistry from Carnegie-Mellon University.

Director Punit Dhillon

Mr. Dhillon has been the President and Chief Executive Officer of Skye Bioscience since 2020. He has a 20-year track record as an executive and investor in the life sciences industry.

Focusing on early-stage biotechs from start-up through clinical proof-of-concept, he has raised more than $500 million in capital and established multiple pharmaceutical partnerships. At Skye he led the strategic acquisition of a novel peripheral CB1 inhibitor for obesity and other metabolic diseases, attracted specialist life science investors, and built out an expert board and management team. Mr. Dhillon was previously the co-founder and former CEO of OncoSec Medical, a developer of cancer immunotherapies and established collaborations with Merck and Genentech.

Prior to Skye he was a managing director of a private San Diego-based pharmaceutical company where he launched an Asia-focused licensing business unit evaluating opportunities in Korea, China, Japan, and the US, and completed a partnership with BMS. He was formerly a director of the Emerald group of companies with responsibility for private equity investments, operations and business development. As Vice President, Finance and Operations, at Inovio Pharmaceuticals he completed licensing deals with Merck, Wyeth (now Pfizer) and Roche. Punit holds a BA (Honors) in political science and a minor in business administration from Simon Fraser University.

Director Annalisa Jenkins, MBBS, FRCP

Annalisa Jenkins, M.B.B.S., F.R.C.P. is a biopharma thought leader whose career spans over 25 years in the global pharmaceutical, biotechnology and life sciences industries.

Dr. Jenkins has broad leadership experience that have resulted in the advancement of new products and cures across multiple disease areas from discovery through to clinical development, regulatory approval, commercialization as well as business exits worldwide. Dr. Jenkins currently provides board level and consulting services to organizations across the life science and healthcare industry. She previously served as President and CEO of Plaquetec Therapeutics and of Dimension Therapeutics, leading efforts to develop novel approaches in coronary vascular and rare diseases that included a significant worldwide partnership for a gene therapy approach to hemophilia A with Bayer Pharmaceuticals. She led Dimension Therapeutics through a public listing on NASDAQ and acquisition by Ultragenyx. In prior leadership roles she was Head of Global Research and Development and Executive Vice President Global Development and Medical at Merck Serono and held several senior positions at Bristol Myers-Squibb over 15 years – including serving as Senior Vice President and Head of Global Medical Affairs.

Dr. Jenkins sits on a number of boards across the public and private sectors and as a trustee of nonprofit organizations globally, including AVROBIO, COMPASS Pathways, MEREO Biopharmaceuticals, AFFIMED, The British Heart Foundation, The King’s Fund, Cancer Research Horizons, Genomics England and Faster Cures at the Milken Institute. As a pharmaceutical thought leader, Dr. Jenkins routinely contributes publicly on leadership with purpose, social entrepreneurship, diversity and innovation.

Dr. Jenkins was commissioned by the British Royal Navy as a Surgeon Sub Lieutenant prior to graduating in medicine from St. Bartholomew’s Hospital in the U.K. Dr. Jenkins served as a medical officer in the British Royal Navy for nine years, achieving the rank of Surgeon Lieutenant Commander.

Director Andy Schwab

Andy Schwab has an established career in the life sciences industry, bringing decades of experience to his role as a Founder and Managing Partner of 5AM Ventures.

Mr. Schwab has led investments in numerous biotech companies such as Bird Rock Bio, Camp4 Therapeutics, DVS (acquired by Fluidigm), Enliven (NASDAQ ELVN), Escient Pharmaceuticals, and Flexion Therapeutics (acquired by Pacira), among others. Before the formation of 5AM in 2002, Schwab was a Principal at Bay City Capital where he contributed to the growth of companies like Cubist, PTC Therapeutics, and Syrrx. His past roles also include Vice President of Business Development at Digital Gene Technologies and a vice president in the life science investment banking group of Montgomery Securities. In 2021, he became a board member at Pear Therapeutics. Concurrently, he has been serving as co-Chief Executive Officer and a member of the board of directors of 5:01 Acquisition Corp. (Nasdaq: FVAM) since its inception in August 2020. Schwab earned a BS with Honors in Genetics & Ethics from Davidson College and currently serves on its board of trustees as well as the Board of Trustees of the California Academy of Sciences.

Director Karen Smith,MD, PhD, MBA, LLM

Karen Smith, MD, PhD, MBA, LLM, has served as a C-suite biotech industry consultant and pharmaceutical executive, member of the board and clinical and scientific advisor during her 20-year career.

Dr. Smith has held various roles, including Chief Executive Officer, Chief Medical Officer, and President. She is a company builder and advocate for women in science and diversity in the boardroom. She currently serves on the boards of Sangamo Therapeutics, Aurinia Pharma, Capstan Therapeutics, and Mariana Oncology. Previously, Dr. Smith served on the boards of Talaris Therapeutics, Forward Pharmaceuticals, Sucampo Pharmaceuticals, Acceleron Pharma, Antares Pharma, all of which were acquired. Prior to these roles, Dr. Smith held leadership roles at Allergan, AstraZeneca, and Bristol-Myers Squibb.

Chairman of the Board Paul Grayson

Paul Grayson brings over 25 years’ experience in the biotech sector.

Mr. Grayson serves as Chief Executive Officer of Radionetics. He has been focusing on company origination, platform validation, IND enablement, and large and small molecule CMC through clinical proof of concept across a broad range of technologies and applications as both a CEO and a Venture Partner over the past 25 years. He was most recently the President and CEO of Tentarix Biotherapeutics, an oncology company focused on multi-functional biologics. His previous experiences also include founding roles at BirdRock Bio (acquired by Skye Biosciences), Fate Therapeutics (NASDAQ: FATE), Senomyx (acquired by Firmenich), and Aurora Biosciences (acquired by Vertex Pharmaceuticals).

Director Deborah Charych, PhD

Deborah Charych, PhD has over 20 years of experience in the biotech and pharmaceutical industry.

Dr. Deborah Charych brings extensive experience in scientific leadership to her role as a co-founder and former Chief Technology Officer of RayzeBio, an oncology company focused on targeted delivery of radionuclides. She conceived and led the scientific and operational R&D strategy for RayzeBio, which led to a successful $45M Series A financing and launch in August, 2020, and subsequent Series B, C and D rounds, with capital raised amounting to $418M. Previously, at Nektar Therapeutics Dr. Charych conceived and led the preclinical and early clinical development of an immuno-oncology pipeline, leading to a $1.8B upfront deal with Bristol Myers Squibb. She also contributed to basic research exploring GPCR receptor biology including the cannabinoid receptor system. At FivePrime Therapeutics, Deborah led a team developing biologics for oncology and autoimmune diseases. While at Chiron Corporation she initiated and led a large proteomics effort to guide oncology target discovery. At Lawrence Berkeley National Laboratory, she led an academic team as a tenured principal investigator, focusing on new biomaterials. Dr. Charych has a Ph.D. in Chemistry from UC Berkeley and a B.S. in Chemistry from Carnegie-Mellon University.

Director Punit Dhillon

Mr. Dhillon has been the President and Chief Executive Officer of Skye Bioscience since 2020. He has a 20-year track record as an executive and investor in the life sciences industry.

Focusing on early-stage biotechs from start-up through clinical proof-of-concept, he has raised more than $500 million in capital and established multiple pharmaceutical partnerships. At Skye he led the strategic acquisition of a novel peripheral CB1 inhibitor for obesity and other metabolic diseases, attracted specialist life science investors, and built out an expert board and management team. Mr. Dhillon was previously the co-founder and former CEO of OncoSec Medical, a developer of cancer immunotherapies and established collaborations with Merck and Genentech.

Prior to Skye he was a managing director of a private San Diego-based pharmaceutical company where he launched an Asia-focused licensing business unit evaluating opportunities in Korea, China, Japan, and the US, and completed a partnership with BMS. He was formerly a director of the Emerald group of companies with responsibility for private equity investments, operations and business development. As Vice President, Finance and Operations, at Inovio Pharmaceuticals he completed licensing deals with Merck, Wyeth (now Pfizer) and Roche. Punit holds a BA (Honors) in political science and a minor in business administration from Simon Fraser University.

Director Annalisa Jenkins, MBBS, FRCP

Annalisa Jenkins, M.B.B.S., F.R.C.P. is a biopharma thought leader whose career spans over 25 years in the global pharmaceutical, biotechnology and life sciences industries.

Dr. Jenkins has broad leadership experience that have resulted in the advancement of new products and cures across multiple disease areas from discovery through to clinical development, regulatory approval, commercialization as well as business exits worldwide. Dr. Jenkins currently provides board level and consulting services to organizations across the life science and healthcare industry. She previously served as President and CEO of Plaquetec Therapeutics and of Dimension Therapeutics, leading efforts to develop novel approaches in coronary vascular and rare diseases that included a significant worldwide partnership for a gene therapy approach to hemophilia A with Bayer Pharmaceuticals. She led Dimension Therapeutics through a public listing on NASDAQ and acquisition by Ultragenyx. In prior leadership roles she was Head of Global Research and Development and Executive Vice President Global Development and Medical at Merck Serono and held several senior positions at Bristol Myers-Squibb over 15 years – including serving as Senior Vice President and Head of Global Medical Affairs.

Dr. Jenkins sits on a number of boards across the public and private sectors and as a trustee of nonprofit organizations globally, including AVROBIO, COMPASS Pathways, MEREO Biopharmaceuticals, AFFIMED, The British Heart Foundation, The King’s Fund, Cancer Research Horizons, Genomics England and Faster Cures at the Milken Institute. As a pharmaceutical thought leader, Dr. Jenkins routinely contributes publicly on leadership with purpose, social entrepreneurship, diversity and innovation.

Dr. Jenkins was commissioned by the British Royal Navy as a Surgeon Sub Lieutenant prior to graduating in medicine from St. Bartholomew’s Hospital in the U.K. Dr. Jenkins served as a medical officer in the British Royal Navy for nine years, achieving the rank of Surgeon Lieutenant Commander.

Director Andy Schwab

Andy Schwab has an established career in the life sciences industry, bringing decades of experience to his role as a Founder and Managing Partner of 5AM Ventures.

Mr. Schwab has led investments in numerous biotech companies such as Bird Rock Bio, Camp4 Therapeutics, DVS (acquired by Fluidigm), Enliven (NASDAQ ELVN), Escient Pharmaceuticals, and Flexion Therapeutics (acquired by Pacira), among others. Before the formation of 5AM in 2002, Schwab was a Principal at Bay City Capital where he contributed to the growth of companies like Cubist, PTC Therapeutics, and Syrrx. His past roles also include Vice President of Business Development at Digital Gene Technologies and a vice president in the life science investment banking group of Montgomery Securities. In 2021, he became a board member at Pear Therapeutics. Concurrently, he has been serving as co-Chief Executive Officer and a member of the board of directors of 5:01 Acquisition Corp. (Nasdaq: FVAM) since its inception in August 2020. Schwab earned a BS with Honors in Genetics & Ethics from Davidson College and currently serves on its board of trustees as well as the Board of Trustees of the California Academy of Sciences.

Director Karen Smith,MD, PhD, MBA, LLM

Karen Smith, MD, PhD, MBA, LLM, has served as a C-suite biotech industry consultant and pharmaceutical executive, member of the board and clinical and scientific advisor during her 20-year career.

Dr. Smith has held various roles, including Chief Executive Officer, Chief Medical Officer, and President. She is a company builder and advocate for women in science and diversity in the boardroom. She currently serves on the boards of Sangamo Therapeutics, Aurinia Pharma, Capstan Therapeutics, and Mariana Oncology. Previously, Dr. Smith served on the boards of Talaris Therapeutics, Forward Pharmaceuticals, Sucampo Pharmaceuticals, Acceleron Pharma, Antares Pharma, all of which were acquired. Prior to these roles, Dr. Smith held leadership roles at Allergan, AstraZeneca, and Bristol-Myers Squibb.

Careers

We seek talented individuals who share our passion to join us on our mission. Browse Skye’s job openings below.

*Please note we are not using external recruiting agencies for the roles